ADMA Biologics

174 articles about ADMA Biologics

• ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023Conference Call Scheduled for May 10, 2023, at 4:30 p.m. ET

  5/3/2023

  ADMA Biologics, Inc. today announced that it will report first quarter 2023 financial results on May 10, 2023, after the U.S. financial markets close.

• ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/23/2023

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2022 financial results and provided a business update.

• ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

  3/16/2023

  ADMA Biologics, Inc. today announced that it will report fourth quarter and full year 2022 financial results on March 23, 2023, after the U.S. financial markets close.

• ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

  2/8/2023

  ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana.

• ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

  12/13/2022

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”) today announced the United States Food and Drug Administration’s (“FDA”) approval for its supplemental Biologics License Applications (BLAs) for both ASCENIV and BIVIGAM to now include room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.

• ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  12/9/2022

  ADMA Biologics, Inc. today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share.

• ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

  12/7/2022

  ADMA Biologics, Inc. priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.

• ADMA Biologics Announces Proposed Public Offering of Common Stock - December 06, 2022

  12/6/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it intends to offer shares of its common stock for sale in an underwritten public offering.

• ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

  12/6/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced preliminary estimates for its total revenue for the quarter- and year-ended December 31, 2022.

• ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

  11/9/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced its third quarter 2022 financial results and provided a business update.

• ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

  11/2/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it will report financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022, after the U.S. financial markets close.

• ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

  10/31/2022

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its seventh ADMA BioCenters plasma collection facility located in Greensboro, North Carolina.

• ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

  8/10/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced its second quarter 2022 financial results and provided a business update.

• ADMA Biologics Announces Addition to the Russell 2000® Index

  6/21/2022

  ADMA Biologics, Inc. announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022.

• ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

  5/11/2022

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its first quarter 2022 financial results and provided a business update.  

• ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET

  5/4/2022

  ADMA Biologics, Inc. today announced that it will report financial results for the first quarter ended March 31, 2022 on Wednesday, May 11, 2022, after the U.S. financial markets close.

• ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

  4/1/2022

  ADMA Biologics, Inc. announced a poster presentation and exclusive Key Opinion Leader symposium by nationally recognized clinical experts on the management of respiratory viral infections and real-world experience with ADMA’s ASCENIV, a U.S. Food and Drug Administration -approved intravenous immunoglobulin product with a unique composition.

• ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

  3/25/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration’s approval to extend the expiration dating from 24 to 36 months for both its ASCENIV and BIVIGAM immune globulin drug product stored at 2-8°C.

• ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

  3/24/2022

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2021 financial results.

• ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

  3/21/2022

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 24, 2022 after the U.S. financial markets close.